Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
Nuclear factor kappa B (NF-κB) is a transcriptional factor that can be activated by radiotherapy and chemotherapy. The synthetic protease inhibitor nafamostat mesilate (NM) inhibits NF-κB activity and exerts antitumor actions in various types of cancer. In the present study, we hypothesized that NM...
Guardado en:
Autores principales: | Naoki Takada, Hiroshi Sugano, Yoshihiro Shirai, Nobuhiro Saito, Ryoga Hamura, Tomohiko Taniai, Tadashi Uwagawa, Katsuhiko Yanaga, Toru Ikegami, Toya Ohashi, Ken Eto |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/57ecd7a11fee43a397cbac4cb04ddc4f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Kyunglan Moon, et al.
Publicado: (2021) -
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
por: Kun Li, et al.
Publicado: (2021) -
Gallbladder fossa volume decreased in livers without gallbladders: A cadaveric study.
por: Diana C J Rhodes, et al.
Publicado: (2021) -
Biliary tract and gallbladder cancer diagnosis and therapy /
Publicado: (2009) -
Case of the Very Rare Gallbladder Paraganglioma
por: Shukla Shreya, et al.
Publicado: (2021)